By logging on to this site you will be leaving the UAMS site and going to a
secure site hosted by EDoc America.
First Time Users
Click on the button below to register for your account
Returning Users
Current Trials
The following clinical trials are currently enrolling patients. Please contact Rebecca if you have questions about a trial or would like to refer a patient to one of these trials. Our research office can also assist you in locating other clinical trials that might be available for your patients.
Prostate Cancer
CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CTSU E3805)
Treatment: docetaxel, androgen ablation
Brief Eligibility Criteria:
· Histologically or cytologically confirmed prostate cancer
· Extensive metastatic disease (visceral or bone)
· On androgen deprivation therapy for less than 90 days
Prostate Cancer
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone (CTSU 90202)
Treatment: zoledronic acid
Brief Eligibility Criteria:
· Histologically confirmed adenocarcinoma of the prostate
· At least 1 bone metastasis by bone scan, MRI, CT scan, or plain radiographs
· Concurrent androgen deprivation therapy required, defined as any of the following:
o Bilateral orchiectomy
o Gonadotropin-releasing hormone (GnRH) agonist with or without an antiandrogen
Prostate Cancer
A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone With and Without Bevacizumab (IND #7921, NSC #704865) In Men With Hormone Refratory Prostate Cancer (CTSU 90401)
Treatment: docetaxel, prednisone, bevacizumab
Brief Eligibility Criteria:
· Histologically confirmed adenocarcinoma of the prostate
· Meets 1 of the following criteria:
o Measurable disease with any level of prostate-specific antigen (PSA)
o Nonmeasurable disease AND PSA ≥ 5 ng/mL
· Progressive systemic disease (since the most recent change in therapy) despite castrate levels of testosterone due to orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist therapy
Prostate Cancer
Randomized, Open Label Multi-Center Study of XRP6258 in Combination With Prednisone Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen
Treatment: XRP6258 or mitoxantrone
Brief Eligibility Criteria:
· Histologically or cytologically confirmed adenocarcinoma of the prostate.
· Documented progression of disease (demonstrating at least one visceral or soft tissue metastatic lesion, including a new lesion). Patients with non-measurable disease must have documented rising PSA levels or appearance of new lesion.
· Surgical or hormone-induced castration
Prostate Cancer
Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
· Histologically confirmed adenocarcinoma of the prostate
· Clinically localized, stage T1-3a disease
o No radiographic evidence of metastatic disease
· Serum prostate-specific antigen level ≤ 100 ng/mL within the past 6 weeks
· High-risk disease
o Probability of biochemical progression-free survival at 5 years after surgery < 60% by Kattan nomogram prediction
Renal Cancer
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma (CTSU E2805)
Treatment: sorafenib, sunitinib
Brief Eligibility Criteria:
· Histologically or cytologically confirmed renal cell carcinoma
· Meets 1 of the following risk categories:
o Intermediate high-risk disease
§ pT1b, G3-4
§ pT2, G1-2
§ pT2, G3-4
§ pT3a, G1-2 (if pT3a is not due to adrenal involvement)
o Very high-risk disease
§ pT3a, G3-4
§ pT3a, any G (if pT3a is due to adrenal involvement)
§ pTb or pTc, any G
§ pT4, any G
§ Any pT, any G, any N+
· No evidence of residual or metastatic renal cell cancer
University of Arkansas for Medical Sciences
Department of Urology
Section of Genitourinary Oncology 4301 W. Markham #774, Little Rock, AR 72205, 501-296-1545
